DMAC on Nasdaq

DiaMedica Therapeutics Inc.

We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) /.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Catabasis Pharmaceuticals, EXICURE, INC. or Imunon, Inc., or pick any stock.

  • TickerDMAC on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMinneapolis, Minnesota1
  • Incorporated inCanada (Federal Level)2
  • Business address301 Carlson Parkway, Suite 210, Minneapolis, Mn 553052
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AIS. Kallikrein-1 (KLK1), extracted from human urine, is an established therapeutic modality in Asia for the treatment of AIS, and KLK1 produced from pig pancreas, is an established therapeutic modality for the treatment of cardio renal disease, including hypertension, in Asia. We plan to advance DM199 through required clinical…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$34.4M in 2025+197% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$11.6M-$11.6M20192020: -$12.7M-$12.7M2020+10%2021: -$13.6M-$13.6M2021+7%2022: -$14.0M-$14.0M2022+3%2023: -$21.3M-$21.3M2023+52%2024: -$26.7M-$26.7M2024+25%2025: -$34.4M-$34.4M2025+29%
Net income456789-$32.8M in 2025+208% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$10.6M-$10.6M20192020: -$12.3M-$12.3M2020+15%2021: -$13.6M-$13.6M2021+11%2022: -$13.7M-$13.7M2022+1%2023: -$19.4M-$19.4M2023+42%2024: -$24.4M-$24.4M2024+26%2025: -$32.8M-$32.8M2025+34%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$24.6M$19.1M
General and administrative$9.8M$7.6M
Total operating expenses$34.4M$26.7M
Operating loss-$34.4M-$26.7M
Other income, net$1.7M$2.3M
Total other income, net$1.7M$2.3M
Loss before income tax expense-$32.7M-$24.4M
Income tax expense-$28.0K-$30.0K
Net loss-$32.8M-$24.4M
Unrealized gain on marketable securities$27.0K$17.0K
Comprehensive loss-$32.7M-$24.4M
Basic and diluted net loss per share (in dollars per share)-$0.70-$0.60
Weighted average shares outstanding basic and diluted (in shares)47.0M shares40.4M shares

Compare DiaMedica Therapeutics Inc. with another company

Leadership

Who has led DiaMedica Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dietrich John Pauls2018–now

President

  1. Dietrich John Pauls2018–now

Chief financial officer

  1. Scott Kellen2018–now
20202025
Board members and other officers (18)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerLorianne Masuoka named Jul 2, 2024 to Jul 25, 202531
  • Executive Officer, DirectorRick Pauls named Oct 6, 2021 to Jul 25, 202531
  • DirectorDaniel T. O'Connor named Jul 25, 202531
  • DirectorMichael R. Giuffre named Oct 6, 2021 to Jul 25, 202531

Former names

  • DiaMedica Inc.May 16, 2007 to Mar 11, 20142

Timeline

  1. Dec 6, 2018New chief executive Dietrich John Pauls becomes CEO12

Filings

261 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 113 insider forms, 23 large holders, 5 private raises, 50 other. The latest 20:

  1. Aug 12, 20264 EDGAR
  2. Aug 11, 2026S-8 EDGAR
  3. Aug 10, 202610-Q EDGAR
  4. Aug 10, 20268-K EDGAR
  5. Jun 3, 20264 EDGAR
  6. Jun 3, 20264 EDGAR
  7. Jun 3, 20264 EDGAR
  8. Jun 3, 20264 EDGAR
  9. Jun 3, 20264 EDGAR
  10. Jun 3, 20264 EDGAR
  11. Jun 3, 20264 EDGAR
  12. Jun 3, 20264 EDGAR
  13. Jun 3, 20264 EDGAR
  14. May 21, 20268-K EDGAR
  15. May 6, 202610-Q EDGAR
  16. May 6, 20268-K EDGAR
  17. Apr 1, 2026ARS EDGAR
  18. Apr 1, 2026DEFA14A EDGAR
  19. Apr 1, 2026DEF 14A EDGAR
  20. Mar 31, 20268-K EDGAR

The 261 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

43 open-market trades by officers, directors and large owners since October 2021: 42 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 25, 2025TRILL AB10% ownerBuy73,099$8.57$626.5KForm 4
Nov 24, 2025TRILL AB10% ownerBuy40,253$7.89$317.6KForm 4
Nov 21, 2025TRILL AB10% ownerBuy208,872$7.41$1.5MForm 4
Nov 20, 2025TRILL AB10% ownerBuy128,426$7.41$951.6KForm 4
Nov 19, 2025TRILL AB10% ownerBuy240,352$7.21$1.7MForm 4
Nov 18, 2025TRILL AB10% ownerBuy182,882$6.75$1.2MForm 4
Nov 17, 2025TRILL AB10% ownerBuy187,393$6.52$1.2MForm 4
Aug 27, 2025STAHLBERG JAN10% ownerBuy50,772$6.00$304.6KForm 4
Aug 26, 2025STAHLBERG JAN10% ownerBuy59,648$6.00$357.9KForm 4
Aug 25, 2025STAHLBERG JAN10% ownerBuy338,265$6.00$2.0MForm 4
Aug 22, 2025STAHLBERG JAN10% ownerBuy59,788$5.96$356.3KForm 4
Aug 21, 2025STAHLBERG JAN10% ownerBuy48,172$5.96$287.1KForm 4
Aug 20, 2025STAHLBERG JAN10% ownerBuy71,107$5.86$416.7KForm 4
Aug 15, 2025STAHLBERG JAN10% ownerBuy8,233$6.00$49.4KForm 4
Aug 14, 2025STAHLBERG JAN10% ownerBuy70,414$5.99$421.8KForm 4
Aug 13, 2025STAHLBERG JAN10% ownerBuy293,601$5.91$1.7MForm 4
Jul 23, 2025JACINTO RICHARD II10% ownerBuy400,000$3.50$1.4MForm 4
Jul 23, 2025STAHLBERG JAN10% ownerBuy1,542,857$3.50$5.4MForm 4
Jul 23, 2025Von Koch Thomas10% ownerBuy2,857,142$3.50$10.0MForm 4
Jun 28, 2024TomEnterprise Private AB10% ownerBuy1,200,000$2.50$3.0MForm 4

All 43 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 23, 2025Raised $30.1 million in a private offering of equity Form D: 14 investors so far Form D
  2. Jun 28, 2024Raised $11.8 million in a private offering of equity Form D: 10 investors so far Form D
  3. Jun 23, 2023Raised $37.5 million in a private offering of equity Form D: 34 investors so far Form D
  4. Apr 10, 2023Raised $750,000 in a private offering of equity Form D: 1 investor so far Form D
  5. Sep 28, 2021Raised $30 million in a private offering of equity Form D: 10 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 89. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cooperman Leon G3,450,000$24.3M0.7%+1,430,000
BlackRock, Inc.2,252,285$15.9M0.0%+396,098
Geode Capital Management, LLC894,115$6.3M0.0%+113,599
Millennium Management LLC845,309$6.0M0.0%−90,283
State Street Corp646,743$4.6M0.0%+2,532
Bleichroeder LP382,317$2.7M0.5%No change
Vanguard Capital Management LLC355,523$2.5M0.0%+22,067
Osaic Holdings, Inc.338,107$2.4M0.0%+18,432
Northern Trust Corp327,518$2.3M0.0%−11,008
Vanguard Portfolio Management LLC251,671$1.8M0.0%+48,212
LPL Financial LLC233,500$1.6M0.0%+7,450
Vanguard Fiduciary Trust Co207,438$1.5M0.0%+19,714
Goldman Sachs Group Inc168,066$1.2M0.0%+108,778
Citadel Advisors LLC145,870$1.0M0.0%+146
Squarepoint Ops LLC145,247$1.0M0.0%New
Bank of New York Mellon Corp117,820$829.4K0.0%+6,741
Members Wealth LLC101,382$713.7K0.4%No change
Charles Schwab Investment Management Inc96,691$680.7K0.0%+8,270
Cobalt Capital Management, Inc.90,000$633.6K0.5%New
Trexquant Investment LP84,648$595.9K0.0%+62,387
Magnolia Capital Advisors LLC77,405$544.9K0.1%No change
Diametric Capital, LP76,621$539.4K0.1%New
Blue Trust, Inc.69,122$486.6K0.0%No change
Bank Of America Corp /de/57,712$406.3K0.0%+14,944
Bank Of Montreal /can/54,944$386.8K0.0%+36,309

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40